|View printer-friendly version|
|September 08, 2003 4:43 p.m.|
|Teva Announces NDA Submission of Rasagiline as a Treatment for Parkinson's Disease|
Jerusalem, Israel, September 8, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has submitted to the US Food and Drug Administration (FDA) a New Drug Application (NDA) for rasagiline for the treatment of Parkinson's disease (PD). The submission is based on data from three Phase III clinical trials in early and advanced PD patients.